Opinion|Videos|September 30, 2024
Surgical and Radiotherapy Choices in Limited-Stage SCLC
Panelists discuss how the surgical approach to limited-stage small cell lung cancer varies, including the percentage of cases amenable to resection, the preference for lobectomy in stage I-IIA disease, and the role of mediastinal lymph node staging in shaping treatment strategies, alongside considerations for choosing between surgery and radiotherapy, the selection of systemic treatments, and the integration of prophylactic cranial irradiation in treatment plans.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your experience, what percentage of limited-stage disease is amenable to resection and does lobectomy remain the preferred procedure for stage I-IIA (T1-2, N0, M0) disease?
- How often does a surgeon operate on a small cell nodule, and what is the next step in treatment?
- To what degree does mediastinal lymph node staging influence your treatment path?
2. Under what circumstances would surgery vs radiotherapy (SABR ) be a preferred, definitive treatment choice for a patient with stage I-IIA small cell lung cancer (SCLC)?
- How do you approach frontline therapy?
- What factors inform your decision to select systemic treatment and concurrent radiotherapy vs sequential radiotherapy?
- How does prophylactic cranial irradiation factor into your treatment plan for patients with limited-stage SCLC?
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Orelabrutinib Generates Significant Survival Benefits in Treatment-Naive CLL
3
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
4
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
5